{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:26:29Z","timestamp":1788233189908,"version":"build-2803163510"},"reference-count":41,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["11200620"],"award-info":[{"award-number":["11200620"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["3190118"],"award-info":[{"award-number":["3190118"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Alzheimer\u2019s disease (AD) is a neurodegenerative disorder whose prevalence has an incidence in senior citizens. Unfortunately, current pharmacotherapy only offers symptom relief for patients with side effects such as bradycardia, nausea, and vomiting. Therefore, there is a present need to provide other therapeutic alternatives for treatments for these disorders. The 5-HT4 receptor is an attractive therapeutic target since it has a potential role in central and peripheral nervous system disorders such as AD, irritable bowel syndrome, and gastroparesis. Quantitative structure-activity relationship analysis of a series of 62 active compounds in the 5-HT4 receptor was carried out in the present work. The structure-activity relationship was estimated using three-dimensional quantitative structure-activity relationship (3D-QSAR) techniques based on these structures\u2019 field molecular (force and Gaussian field). The best force-field QSAR models achieve a value for the coefficient of determination of the training set of R2training = 0.821, and for the test set R2test = 0.667, while for Gaussian-field QSAR the training and the test were R2training = 0.898 and R2test = 0.695, respectively. The obtained results were validated using a coefficient of correlation of the leave-one-out cross-validation of Q2LOO = 0.804 and Q2LOO = 0.886 for force- and Gaussian-field QSAR, respectively. Based on these results, novel 5-HT4 partial agonists with potential biological activity (pEC50 8.209\u20139.417 for force-field QSAR and 9.111\u20139.856 for Gaussian-field QSAR) were designed. In addition, for the new analogues, their absorption, distribution, metabolism, excretion, and toxicity properties were also analyzed. The results show that these new derivatives also have reasonable pharmacokinetics and drug-like properties. Our findings suggest novel routes for the design and development of new 5-HT4 partial agonists.<\/jats:p>","DOI":"10.3390\/ijms22073602","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:13:10Z","timestamp":1617149590000},"page":"3602","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Understanding the Molecular Basis of 5-HT4 Receptor Partial Agonists through 3D-QSAR Studies"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8360-8027","authenticated-orcid":false,"given":"Alejandro","family":"Castro-Alvarez","sequence":"first","affiliation":[{"name":"Laboratorio de Bioproductos Farmac\u00e9uticos y Cosm\u00e9ticos, Centro de Excelencia en Medicina Traslacional, Facultad de Medicina, Universidad de La Frontera, Av. Francisco Salazar 01145, Temuco 4780000, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9783-0806","authenticated-orcid":false,"given":"Emigdio","family":"Ch\u00e1vez-\u00c1ngel","sequence":"additional","affiliation":[{"name":"Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, Campus UAB, Bellaterra, 08193 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7449-6334","authenticated-orcid":false,"given":"Ronald","family":"Nelson","sequence":"additional","affiliation":[{"name":"Departamento de Qu\u00edmica, Facultad de Ciencias, Universidad Cat\u00f3lica del Norte, Av. Angamos 0610, Antofagasta 1270709, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"McDowell, S.E. (2011). Adverse reactions to drugs used in the treatment of Alzheimer\u2019s disease. Adverse Drug React. Bull., 1031\u20131034.","DOI":"10.1097\/FAD.0b013e328348c804"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1002\/j.1460-2075.1995.tb07280.x","article-title":"The 5-HT4 receptor: Molecular cloning and pharmacological characterization of two splice variants","volume":"14","author":"Gerald","year":"1995","journal-title":"EMBO J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0165-6147(00)89081-1","article-title":"Central 5-HT4 receptors","volume":"16","author":"Eglen","year":"1995","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/1568007043482615","article-title":"5-HT4 receptors","volume":"3","author":"Bockaert","year":"2004","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.coph.2011.01.012","article-title":"5-HT4 receptors, a place in the sun: Act two","volume":"11","author":"Bockaert","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuroscience.2004.06.070","article-title":"Modulation of hippocampal excitability by 5-HT 4 receptor agonists persists in a transgenic model of Alzheimer\u2019s disease","volume":"129","author":"Spencer","year":"2004","journal-title":"Neuroscience"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2174\/1567205043332252","article-title":"New Insights into Serotonin 5-HT4 Receptors: A Novel Therapeutic Target for Alzheimers Disease?","volume":"1","author":"Maillet","year":"2004","journal-title":"Curr. Alzheimer Res."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Rebholz, H., Friedman, E., and Castello, J. (2018). Alterations of Expression of the Serotonin 5-HT4 Receptor in Brain Disorders. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113581"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"104949","DOI":"10.1016\/j.phrs.2020.104949","article-title":"Role of 5-HT receptors in neuropathic pain: Potential therapeutic implications","volume":"159","author":"Liu","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000090309","article-title":"Drugs Acting on Serotonin Receptors for the Treatment of Functional GI Disorders","volume":"24","author":"Tonini","year":"2006","journal-title":"Dig. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2036.2004.02180.x","article-title":"Review article: Serotonin receptors and transporters\u2014Roles in normal and abnormal gastrointestinal motility","volume":"Volume 20","author":"Gershon","year":"2004","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s12272-018-1068-5","article-title":"Recent advances in pharmacological research on the management of irritable bowel syndrome","volume":"41","author":"Nam","year":"2018","journal-title":"Arch. Pharm. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1136\/gut.44.5.682","article-title":"Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans","volume":"44","author":"Bouras","year":"1999","journal-title":"Gut"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e14026","DOI":"10.1111\/nmo.14026","article-title":"Prokinetic actions of luminally acting 5-HT4 receptor agonists","volume":"33","author":"Konen","year":"2020","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e13708","DOI":"10.1111\/nmo.13708","article-title":"Luminal 5-HT4 receptors\u2014A successful target for prokinetic actions","volume":"31","author":"Gwynne","year":"2019","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0531-5565(02)00157-2","article-title":"The serotonin 5-HT4 receptor and the amyloid precursor protein processing","volume":"38","year":"2003","journal-title":"Exp. Gerontol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/13543776.2020.1767587","article-title":"Therapeutic modulators of the serotonin 5-HT4 receptor: A patent review (2014-present)","volume":"30","author":"Lanthier","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"9240","DOI":"10.1021\/jm300953p","article-title":"Identification of Multiple 5-HT 4 Partial Agonist Clinical Candidates for the Treatment of Alzheimer\u2019s Disease","volume":"55","author":"Brodney","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4236\/nm.2011.22013","article-title":"5-HT4 Receptor Agonists for the Treatment of Alzheimer\u2019s Dsease","volume":"02","author":"Ahmad","year":"2011","journal-title":"Neurosci. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"334","DOI":"10.2174\/092986710790192730","article-title":"Serotonin 5-HT3 and 5-HT4 Ligands: An Update of Medicinal Chemistry Research in the Last Few Years","volume":"17","author":"Modica","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejmech.2014.05.015","article-title":"Synthesis and structure\u2013activity relationship studies in serotonin 5-HT4 receptor ligands based on a benzo[de][2,6]naphthridine scaffold","volume":"82","author":"Castriconi","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ejmech.2015.08.051","article-title":"Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer\u2019s disease","volume":"103","author":"Nirogi","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1021\/acs.jmedchem.8b00457","article-title":"Synthesis, Structure\u2013Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT 4 Receptor Partial Agonists","volume":"61","author":"Nirogi","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jmgm.2015.08.001","article-title":"Prediction of dual agents as an activator of mutant p53 and inhibitor of Hsp90 by docking, molecular dynamic simulation and virtual screening","volume":"61","author":"Abbasi","year":"2015","journal-title":"J. Mol. Graph. Model."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1080\/07391102.2015.1077343","article-title":"Pharmacophore model prediction, 3D-QSAR and molecular docking studies on vinyl sulfones targeting Nrf2-mediated gene transcription intended for anti-Parkinson drug design","volume":"34","author":"Athar","year":"2016","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.chemolab.2015.04.013","article-title":"On a simple approach for determining applicability domain of QSAR models","volume":"145","author":"Roy","year":"2015","journal-title":"Chemom. Intell. Lab. Syst."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1080\/07391102.2015.1119732","article-title":"A combination of pharmacophore modeling, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on PDE4 enzyme inhibitors","volume":"34","author":"Tripuraneni","year":"2016","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1080\/08927022.2016.1274987","article-title":"Exploration of potential RSK2 inhibitors by pharmacophore modelling, structure-based 3D-QSAR, molecular docking study and molecular dynamics simulation","volume":"43","author":"Zhu","year":"2017","journal-title":"Mol. Simul."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_30","unstructured":"(2021, February 19). pkCSM. Available online: http:\/\/biosig.unimelb.edu.au\/pkcsm\/."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_32","unstructured":"Molecular Modeling Group (2021, February 19). Swiss Institute of Bioinformatics SwissADME. Available online: http:\/\/www.swissadme.ch\/."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1021\/cc9800071","article-title":"A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases","volume":"1","author":"Ghose","year":"1999","journal-title":"J. Comb. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular Properties That Influence the Oral Bioavailability of Drug Candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1021\/jm000292e","article-title":"Prediction of drug absorption using multivariate statistics","volume":"43","author":"Egan","year":"2000","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1021\/ci100031x","article-title":"Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural Database","volume":"50","author":"Hawkins","year":"2010","journal-title":"J. Chem. Inf. Model."},{"key":"ref_38","first-page":"74","article-title":"Comparison of Shape-Matching and Docking as Virtual Screening Tools","volume":"50","author":"Paul","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1093-3263(01)00123-1","article-title":"Beware of q2!","volume":"20","author":"Golbraikh","year":"2002","journal-title":"J. Mol. Graph. Model."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/minf.201000061","article-title":"Best Practices for QSAR Model Development, Validation, and Exploitation","volume":"29","author":"Tropsha","year":"2010","journal-title":"Mol. Inform."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.drudis.2019.03.015","article-title":"ADMET modeling approaches in drug discovery","volume":"24","author":"Ferreira","year":"2019","journal-title":"Drug Discov. Today"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/7\/3602\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:55:44Z","timestamp":1760363744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/7\/3602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["ijms22073602"],"URL":"https:\/\/doi.org\/10.3390\/ijms22073602","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,30]]}}}